$51.00
Manufacturer: Ukraine
Erbisol is used in complex therapy: gastroenterology: hepatitis of various etiologies (including viral, toxic, and drug-induced hepatitis caused by the use of antibiotics, interferons, chemotherapy drugs, and other potent drugs that cause side effects), reactive hepatitis, steatohepatosis, liver cirrhosis, gastric and duodenal ulcer, erosive gastroduodenitis, and non-specific ulcerative colitis toxicology: ERBISOL enhances liver detoxification functions endocrinology: diabetes mellitus, autoimmune thyroiditis; therapy: non-specific lung diseases (pneumonia, chronic bronchitis), pulmonary tuberculosis, angiopathy, to improve microcirculation, normalize vascular tone and blood filling, metabolic dystrophy.
Description
Erbisol Storage
active substances: 1 ml of the drug contains: a complex of natural non-protein low-molecular organic compounds of non-hormonal origin derived from animal embryonic tissue, oligopeptides and glycopeptides (total 0.07-0.4 mg), nucleotides, amino acids.
Erbisol extra Excipients: 0.9% sodium chloride solution is isotonic.
Erbisol Dosage form
Solution for injection.
Main physicochemical properties: transparent or slightly opalescent colorless or light yellow liquid with a specific odor.
Pharmacotherapeutic group
Immunostimulants. ATX code L03A X.
Drugs that affect the digestive system and metabolism. ATX code A16A X.
Pharmacological properties
Pharmacodynamics.
The pharmacological activity of the drug is determined by the content of low molecular weight biologically active peptides, which have immunomodulatory, reparative, antioxidant and antihypoxic effects.
The main immunomodulatory effect of the drug is manifested primarily through the action on the macrophage link, which is responsible for repairing damaged cells and restoring the functional activity of organs and tissues, as well as through NK cells (CD3-16 + 56 +) and T-killers (CD3 + 16 + 56 +), which are responsible for the destruction of damaged cells incapable of regeneration, or abnormal cells. At the same time the drug has an immunocorrective effect and in immune disorders contributes to its normalization due to the activation of T-lymphocytes, Th1-helpers and T-killers, which is important for restoring the balance between cellular and humoral immunity.
The reparative properties of the drug are due to its immunomodulatory effect, which is manifested by increased activity of macrophages (which cause the repair of damaged cells and restoration of functional activity of organs and tissues), as well as N- and T-killers responsible for destroying damaged cells incapable of regeneration.
The antioxidant effect of the drug is manifested by inhibiting the processes of lipid peroxidation, increasing the activity of glutathione-dependent antioxidant system of the blood, without changes in the activity of microsomal oxidation enzymes and cytochrome P450 content, as well as membrane stabilizing effect at plasma levels.
The drug realizes antihypoxic properties by increasing tissue oxygen consumption and improving tissue respiration by increasing electron transport in mitochondria, restoring the proton gradient on their membranes and shifting the dissociation curve of oxyhemoglobin to the right, ie increases the return of oxygen to tissues.
The drug is non-toxic, devoid of cumulative toxicity, allergenic, teratogenic, mutagenic and carcinogenic properties.
Pharmacokinetics.
Not studied.
Indication
In complex therapy:
cardiovascular diseases: arterial hypertension, cardiomyopathy, myocarditis, coronary heart disease, myocardial infarction, postinfarction cardiosclerosis, diffuse cardiosclerosis;
neurological diseases: cerebral atherosclerosis, stroke, neurological disorders associated with cerebrovascular disorders (after a stroke), polyneuritis of various origins, demyelinating polyneuropathy, Parkinson’s disease;
diseases of the gastrointestinal tract: acute and chronic hepatitis of various etiologies, hepatopathies, hepatosis, liver cirrhosis, pancreatitis, erosive gastroduodenitis, peptic ulcer of the stomach and duodenum, nonspecific ulcerative colitis;
non-specific diseases: non-specific lung diseases (pneumonia, chronic bronchitis), metabolic dystrophies, angiopathy, to improve microcirculation, normalization of vascular tone and blood supply, chronic renal failure, rheumatism, diffuse connective tissue diseases, arthrosis, systemic vasculitis . ERBISOL® Extra is used in the complex treatment of persons affected by the effects of radiation and environmental pollution, the drug has pronounced adaptive and corrective properties, increases the compensatory and protective functions of the body.
diabetes mellitus, thyroiditis, autoimmune insulin syndrome;
periodontitis and periodontitis;
in surgery and traumatology: obliterating diseases of the aorta and its branches of atherosclerotic origin, obliterating endarteritis, diabetic macro- and microangiopathy, traumatic, postoperative and purulent wounds, trophic ulcers of various etiologies, bedsores, fractures for conjunctiva;
in allergology: allergic diseases, including bronchial asthma, atopic dermatitis and atopic rhinoconjunctivitis;
skin diseases: pustular skin diseases, dermatitis and toxicoderma, neurodermatosis, eczema, psoriasis;
in gerontology: functional insufficiency associated with age-related disorders of the liver, immune, nervous and cardiovascular systems. To increase physical activity and overall vitality, potency.
Contraindication
Individual intolerance, hypersensitivity to any component of the drug.
Recent Reviews